a PDUFA in October. • Merck confirms PD-I efficacy in IL PD-L1+ NSCLC with 47% irRC ORIL First data from Merck's phase lb study of pembrolizumab in IL NSCLC showed a 47% (21/45) ORR by irRC (26% based on RECIST) across all three doses, and we note that 80% of patients had at least some tumor shrinkage,